Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486160 | 0.85 | MAPK1 (0.46) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL5490322 | 0.85 | CYP1A2 (0.46) | PGRCYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5484469 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL5492933 | 0.81 | TDP2 (0.47) | TDP2CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5492316 | 0.81 | ALDH1A1 (0.53) | TDP2CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5484921 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL5493764 | 0.80 | MAPK1 (0.49) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL5484416 | 0.80 | CYP11B1 (0.47) | TDP2CYP1A2CYP3A4CYP2C9MAPK1 | |
| SCHEMBL5490244 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL5488323 | 0.79 | KIT (0.44) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | claimed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | TDP2 208/4885PGR 1890/4885CYP1A2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.